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Factors Influencing the Incidence of 
Infections in Felty’s Syndrome
Ferdinand C. Breedveld, MD; Wim E. Fibbe, MD; Jo Hermans, PhD; Jos W. M. van der Meer, MD; Arnold Cats, MD
•  To identify clinical and laboratory risk factors for the 
susceptibility to Infections in Felty’s syndrome, 46 patients 
were studied prospectively during a total number of 431 peri­
ods of three months (“patlent-quarters”). The incidence of 
infections increased significantly with polymorphonuclear 
leukocyte (PMN) counts below 0.1x103/mm3 (<0.1 x 109/L). At 
PMN levels over 0.1 x 103/mm3 (>0.1 x 109/L), no association was 
found between PMN counts and the incidence of infections. 
Other factors found to be associated with an increased inci­
dence of infections were severe disability, skin ulcers, gluco- 
corticosteroid dose, monocyte counts, hypocomplementemia, 
and high levels of circulating immune complexes. The activity 
of the rheumatoid arthritis, erythrocyte sedimentation rate, 
lemoglobin concentrations, and lymphocyte counts were not 
associated with increased incidence of infections.
(Arch Intern Med 1987;147:915-920)
T n  1924, Felty recognized the association of rheumatoid 
^  a r th r i t is  (RA) with leukopenia and splenomegaly .1 Since 
then, the  syndrome has been shown to be associated with a 
lumber of extra-ar t icu lar  manifestations of RA and recur­
rent infections .2'4 Leukopenia in Felty’s syndrome (FS) is 
)rimarily due to neutropenia. Several pathophysiologic 
nechanisms have been reported  to explain the neutropenia, 
e, insufficient granulopoiesis, reduced release of poly- 
norphonuclear cells (PMNs) from the bone marrow, and 
shortened life span or excessive margination of the circulat- 
ng P M N s .3,5"17 Neutropenia is thought to be the main cause 
>f the increased susceptibility to infections ,2,4,5,7,16,18*20 al- 
hough other  clinical factors have also been implicated, ie, 
lypocomplementemia ,21,22 defective function of P M N s ,22,23 
evere disability ,24,25 skin ulcerations ,26 and corticosteroid 
herapy .27
Although the  high risk of infection in FS  has been 
ecognized by many authors, the incidence of such infec- 
ions has, to our knowledge, never been studied prospec­
tively. Furtherm ore ,  most of the published studies have 
been res tr ic ted  to the association between the incidence of 
infections and one particular parameter. We therefore 
i ndertook a prospective study on the relationship between
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the incidence and type of infections in FS and multiple 
clinical factors. Disability, polyarthritis  activity, skin ul­
cers, leukopenia, anemia, hypocomplementemia, levels of 
circulating immune complexes, and the dose of glucocor- 
ticosteroids were all considered as possible contributing 
factors to the incidence of infections.
PATIENTS AND METHODS
Patients
Patients referred to six hospitals, who had been registered by 
the National Committee for Research on Rheumatoid Diseases, 
the Netherlands, under the clinical diagnosis FS, were included in 
this study. For the diagnosis of FS, the patient had to have the 
combination of definite RA according to the American Rheu­
matism Association criteria, sustained neutropenia of under 
2 .0 x l0 3/mm3 (< 2 .0 x l0 9/L) lasting at least six months, and 
splenomegaly. Patients with drug-related marrow toxic reaction or 
myeloproliferative disorders were excluded. The patients were 
treated  with a variety of medications, including nonsteroidal anti­
inflammatory drugs and disease-modifying agents, such as gold 
salts, d-penicillamine, and chloroquine. These drugs were gener­
ally prescribed to trea t  the polyarthritis and not to increase the 
number of circulating PMNs. The neutropenia in FS was treated by 
splenectomy in four patients and by prednisone in nine patients. 
All patients with FS registered between June 1982 and June 1985 
were enrolled. A t the time of enrollment and at three-month 
intervals after that, the patients were examined by one of us and 
blood was collected for laboratory investigation. These three- 
month periods of follow-up will be called “patient-quarters.” Only 
patients with at least one patient-quarter of follow-up were in­
cluded in the study.
Clinical and Laboratory Data
Proved bacterial and fungal infections (ie, proved by culture of 
biopsy) were classified as either major (septicemia or organ 
infection, eg, pneumonia, septic arthritis, pyelonephritis) or minor 
(local infections, eg, stomatitis, bronchitis, skin abscesses, cysti­
tis). Functional capacities were scored according to Steinbrocker et 
al.28 A rthritis  activity was scored according to the Ritchie articular 
index.29 A score of 15 or less was considered as inactive RA and 16 or 
more as active RA. The dosages used for corticosteroid therapy 
were recorded as the highest dose given during the preceding 
patient-quarter. White blood cell counts were recorded at the 
baseline level (ie, in the absence of infection). Immune complexes 
(lex) were measured by Clq binding assay30; the amount of lex was 
expressed as microgram equivalents of a standard of aggregated 
IgG.31 Complement activity was expressed as total hemolytic com­
plement (CHjo) activity.32 Where CHgo activity was decreased, the 
levels of Clq, Cl inhibitor, C3, and C4 were measured by radial im­
munodiffusion using monospecific antisera.33 The C3 through C9
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With Infection, % f Incidence}:
Patient-Quarters 
With Infection, % f Incidence}
PMNs
<0.1 7 18 28 28 61 111
0.1-0.5 15 48 ‘  0 0 8 15
0.5-1.0 19 48 6 6 20 25
1.0-2.0 40 203 4 5 23 31
>2.0 24 114 2 2 11 11
Lymphocytes
<0.1 0 0 •  •  • •  •  • •  •  • •  •  •
0.1-0.5 8 34 9 9 38 47
0.5-1.0 30 150 5 6 18 27
1.0-2.0 33 162 3 3 23 29
>2.0 16 85 3 3 11 13
Monocytes
<0.1 12 55 5 5 40 49
0.1-0.2 34 190 7 8 20 31
0.2-1.0 28 185 1 1 15 16
>1.0-2.0 1 1 •  •  • •  •  • •  •  • •  f  •
*PMN indicates polymorphonuclear leukocyte. Normal values are as follows: PMNs, 2.5 to 7 .0x103/mm3 (2.5 to 7 .0x109/L); lymphocytes, 1.0 to 4.0 x 
103/mm3 (1.0 to 4 .0x109/L); monocytes, 0.2 to 1.0x103/mm3 (0.2 to 1 .0x109/L).
•fPercentage of patient-quarters with at least one documented infection.
¿Number of observed infections per 100 patient-quarters of follow-up.
levels were determined hemolytically.34 Functional activity of Cl 
inhibitor"15 and C236 was assessed with the appropriate hemolytic 
assay.
Infections occurring in one patient-quarter were related to 
clinical and laboratory data documented at the beginning of that 
interval to avoid an influence of infection on these factors. Because 
the individual factors may vary between the various intervals, any 
given patient could have been classified in different subsets of that 
factor, which means that the sum of the number of patients in the 
subsets may exceed the number of patients studied (Table 1).
Statistical Analysis
For evaluation of the contribution made by the clinical factors 
under study to the occurrence of infection, clinical data were 
recorded before each patient-quarter and related to the occurrence 
of infections in the following three months. However, it should be 
noted tha t the patient-quarters were not all independent, since the 
431 quarters  were studied in 46 patients.
The relation between the number of infections per patient- 
quar te r  and the peripheral blood cell count was investigated by 
linear regression. With the regression equation for PMNs and 
monocytes, expected values of the numbers of major as well as of 
maj or and minor infections were computed for the patient-quarters 
of all patients with various subsets of PMN and monocyte counts. 
Next, the ratios of observed-to-expected numbers of infections 
(based on PMN and monocyte counts) were recorded for the 
specific conditions (hypocomplementemia, skin ulcers, etc) being 
evaluated. Observed-to-expected ratios lower than 1 indicate fewer 
infections than would occur by chance, whereas values higher than
1 indicate an increased incidence of infections. To test for an 
association between clinical factors and the occurrence of infec­
tions, 2 x 2 tables were used, ie, percentages of patient-quarters 
with or without infections were compared with percentages of 
patien t-quarters  with or without the factors. We considered 
P  values lower than .05 statistically significant.
RESULTS
Patients
From  June  1982 to June  1985, 46 patients with FS  were 
studied for a mean follow-up period of 9.4 pat ien t-quarters  
(range, one to 12), resulting in a cumulative number of 431 
pa t ien t-quarters .  The mean duration of the neutropenia at
the  time of en try  to the study was four years (range, 0.5 to 
16 years). The mean duration of RA before the recognition of 
the neutropenia was 15 years (range, 0 to 46 years). In most 
of the patients ,  the splenomegaly was documented shortly 
af ter  the discovery of the neutropenia by palpation (26 
patients) or radioisotope scanning (20 patients). All pa­
t ien ts  had symptoms of arthri t is .  At the end of the study, 
the patients  were classified functionally according to Stein- 
brocker et  a l ,28 which gave the following results: grade I, ten 
patients; grade II, 12 patients; grade III ,  12 patients; and 
grade IV, 12 patients. The rheumatoid a r th r i t is  was active 
in 28% of the pa t ien t-quarters  (Table 2).
Hematologic Data
The leukocyte distribution of the patients  during the  431 
pa t ien t-quar te rs  is given in Table 1. There was a weak 
correlation between the peripheral blood counts of PMNs, 
lymphocytes, and monocytes ( r—.20). The PMN counts 
were over 2.0 x 103/mm3 (>2.0 x 109/L) in 26% of the patient- 
quar te rs ,  and the numbers of lymphocytes and monocytes 
were normal in 57% and 43%, respectively. Severe neu­
tropenia  occurred more frequently than severe lympho­
cytopenia (Table 1). Anemia was presen t  in 65% of the 
pa t ien t-quar te rs  (Table 2 ), and platelet counts were below 
the  normal range in 19% of the patien t-quarters .  The 
ery throcyte  sedimentation ra te  was above 100 mm/h in 27% 
and below 50 mm/h in 20% of the pa t ien t-quarte rs  (Table 2).
Serologic Data
Serum rheumatoid factor was presen t  in all patients. 
Forty-five patients  had antinuclear antibodies as well. 
Circulating lex were demonstrated in 80% of the 204 
pa t ien t-quar te rs  in which patient  serum samples were 
investigated for lex. Hypocomplementemia, defined as 
depressed CH^ activity, was presen t  in 30% of the 201 
pa t ien t-quar te rs  investigated. Among the hypocomple- 
mentemic serum samples, C4 activity was lower than nor­
mal in 92%, C2 in 81%, and C3 in 56%. The level of Clq was 
normal in 68%, and Cl inhibitor and the C3-9 complex were
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Table 2 - -Association of Clinical Factors With the Occurrence of Infections in Felty’s Syndrome*






















Active 121 2 3 0.8 25 29 1.1
InactiveII
310 5 5 1.1 21 27 1.0
Functional class
Grade 1 107 2 2 0.2 10 19 0.5
Grade II 138 2 2 0.4 25 31 1.1
Grade III 108 5
#
5 0.5 19 20 1.0




80 13 14 2.6 35 53 1.7
Absent 332 2 3 0.3 17 21 0.8
Prednisone dose, mg
0 353 4 5 0.8 19 24 1.0
1-20 66 5 5 0.8 21 29 0.9
! >20 12 8 8 1.6 42 88 1.8
Westergren ESR, mm/h
<50 86 5 5 0.9 22 34 0.9
50-100 230 4 4 1.1 21 25 1.0
>100 115 5 6 1.0 20 24 1.1
Hemoglobin, g/dL (g/L)
<8 (<80) 5 0 0 0 20 20 1.2
8-12 (80-120) 275 5 5 0.9 21 23 0.9
>12 (>120) 151 4 4 1.2 30 32 1.1
CH50 activity
Decreased 60 17 18 3.2 40 58 1.7
Normal 141 4 4 0.5 23 31 1.1
Immune complexes, p.g Eq/mL
<10 40 0 0 0 10 10 0.5
10-1000 130 8 9 1.8 26 38 1.3
>1000 34 18 18 2.2 60 91 2.2
*ESR indicates erythrocyte sedimentation rate; CH^, total hemolytic complement. 
tPercentage of patient-quarters with at least one documented infection.
^Calculated number of infections per 100 patient-quarters.
§Quotient of observed number of infections and expected number of infections based on polymorphonuclear leukocyte and monocyte counts.
normal in all patients.  A pa t te rn  of decreased C4 and C2 
concentrations with normal amounts of the C3-9 complex 
implies complement activation via the classic pathway. The 
presence of hypocomplementemia was significantly corre­
lated with the presence of lex levels above 1000 \±g Eq/mL 
(P<.001). Hypocomplementemia was not observed in pa ­
t ien t-quarters  in which no circulating lex could be detected.
Infections
A total of 115 infections (20 major, 95 minor) were 
diagnosed during the study, resulting in an overall infection 
rate of 27 per  100 patient-quarters .  These infections oc­
curred in 22% of the patient-quarters .  The major infections 
were observed in only 14 patients. These patients  were 
studied for a mean of 8.4 pat ien t-quarters  (range, th ree  to 
12). The 95 minor infections were distr ibuted over 34 
patients studied during a mean of 9.7 pa t ien t-quarte rs  
(range, two to 12). Infecting organisms and isolation sites 
are given in Table 3. Staphylococcus aureus  was the most 
commonly isolated organism, occurring in 50% of the major 
and 32% of the minor infections. P seudom onas aeruginosa , 
Esckerichia coli, and o ther  Enterobacteriaceae toge ther  
accounted for 43% of the isolations from patients  with major
infections and 45% with minor infections. There were four 
infections with C andida albicans. Disseminated or deep- 
tissue fungal infections, severe viral infections, and infec­
tions caused by intracellular bacteria (eg, mycobacteria) 
were not observed. Bacteremia occurred in ten patients 
in association with major organ infection and in four pa ­
t ients  without a major organ infection (Table 3). Four pa­
tients  died of major organ infection and sepsis during the 
study.
Leukocytes and Infection
The percentage of pat ien t-quarters  with documented 
major or all (major and minor) infections increased sig­
nificantly when PMN counts were under  0 .1 x l0 3/mm3 
(< 0 .1x l07L ) ,  ( P < . 001, P M N s< 0 .1 x  107mm3 vs PMNs 
>0.1 x 107mm3 [P M N s< 0 .1 x l0 7 L  vs P M N s> 0 .1 x  107L]) 
(Table 1). The incidence of major infections rose strongly 
from fewer than six infections per  100 pa t ien t-quarte rs  at 
PMN counts over 0 .1 x l0 3/mm3 (> 0 .1 x l0 7 L )  to 28 when 
PMN counts were under  0.1 x 103/mm3 ( < 0.1 x 107L) (Table 
1). For all infections, these figures were fewer than  31 
infections per  100 pa t ien t-quarters  with over 0 .1 x l 03/mm3 
(> 0 .1 x l0 7 L )  and 111 per  100 pat ien t-quarters  with under
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Table 3.—Types of Infection and Causative Organisms
in 46 Patients With Felty’s Syndrome
Gram- Gram- 
Positive Negative 
lype of Infection Cocci Rods Mixed Candida
Major
Septic arthritis 2 0 • • • • •
Osteomyelitis 2 0 • • t • •
Muscle abscess 2 0 • •
Pneumonia 3 0 • 0 • • •
Septic pericarditis 1 0 • •
Pyelonephritis 0 2 0 •
Diverticulitis 0 2 • •
Meningitis 1 0 • •
Ecthyma gangrenosum 0 1 • •
Bacteremia without other 
types of major infection 3 1 • • • • •
Total 14 6 • • • • •
Minor
Conjunctivitis 1 1 0 0
Stomatitis 1 0 1 1
Pharyngitis 5 0 1 0
Sinusitis 2 2 2 0
Otitis media 1 1 0 0
Esophagitis 0 0 0 3
Bronchitis 0 11 4 0
Cystitis 0 26 0 0
Skin abscess 12 0 12 0
Cellulitis 6 0 2 0
Total 28 41 22 _ 4
0.1 x 103/mm3 ( < 0.1 x 109/L). Individual patients  with highly 
variable PMN counts during the study period also devel­
oped infections more frequently at PMN counts under
0.1 x 107mm3 (<0 .1x l07L) .
In the presence of lymphocytopenia and monocytopenia, 
the percentage of pat ien t-quarters  with at least one docu­
mented major or minor infection was also increased (Table 
1). Multiple regression analysis showed the PMN counts 
under  0.1 x 103/mm3 (<0.1 x 107L) to be the most important  
determinative factor for the increased incidence of infec­
tion; the  influence of monocyte counts under 0 .1 x l 03/mma 
(< 0 .1 x l0 7 L )  on all infections was small (P < .05  vs mono­
cytes counts over 0 .1 x l0 3/mm3 [> 0 .1x l07L ] ;  not signifi­
cant for major infections) and lymphocyte counts did not 
make an independent contribution apar t  from the PMN and 
monocyte counts.
Role of Arthritis Activity, Disability,
Skin Ulceration, and Glucocorticosteroid Therapy
Patients  with active and inactive polyarthritis  had similar 
ra tes  of infection, being two and five per  100 patient- 
quar te rs ,  respectively, for major infections. For all infec­
tions, 25 per  100 patient-quarters  were associated with 
infection when the arthr i t is  was active, against 21 per  100 
pat ien t-quarte rs  when the ar thr i t is  was inactive (Table 2).
Next,  the role of disability was investigated. The percen t­
age of pat ien t-quarters  with documented infections was 
significantly higher (P <.01  for major and for all infections) 
in patients  incapable of any self-care (grade IV) than in 
patients  capable of all daily activities (grade I; Table 2). The 
influence of disability alone was assessed by calculating the 
expected number of infections on the basis of the PMN and 
monocyte counts documented in the pat ien t-quarters  with
different functional grades. The observed-to-expected ratio 
for major infections in pat ien t-quarters  with functional 
grade IV was 2.2 vs 0.2 in pat ien t-quarters  with functional 
grade I. For all infections, these ratios were 1.5 and 0.5. 
Pa t ien t-quarte rs  with functional grades II and I I I  were 
associated with a higher incidence of all infections compared 
with pa t ien t-quarte rs  with functional grade I, although for 
major infections alone, no difference was found.
During pa t ien t-quarte rs  in which skin ulcers were ob­
served, the percentage of intervals with documented major 
infections was 13% compared with 2% in intervals without 
ulcers (P<.01). For all infections, 35% of the intervals were 
associated with infection when ulcers were p resen t  as 
against 17% in the absence of ulcers (P<.01). The observed- 
to-expected ratio for major infections in pat ien t-quarters  
with ulcerations was 2.6 vs 0.3 in pa t ien t-quarte rs  without 
ulcerations. For all infections, this ratio was 1.7 with ulcers 
vs 0.8 in the ir  absence (Table 2). Pa t ien t-quarte rs  during 
which prednisone was given in a daily dose of less than  20 
mg were associated with frequencies of infection similar to 
those for quar te rs  without glucocorticosteroid therapy. 
Pat ien t-quarters  during which patients  received more than 
20 mg of prednisone per  day had a higher incidence of 
infection and an observed-to-expected ratio for infection 
higher than 1 (Table 2). However, this association was not 
statistically significant.
Role of Hematologic and Serologic Factors
When pa t ien t-quarte rs  were grouped according to the 
Westergren erythrocyte  sedimentation rate  in subsets  of 
under  50, 50 to 100, and over 100 mm/h, no difference was 
found in the association with e i ther  major infections or all 
infections (Table 2). Pa t ient-quarters  grouped according to 
hemoglobin concentrations in subsets  of under  8 , 8 to 12, 
and over 12 g/dL (<80, 80 to 120, >  80 g/L) also showed no 
difference in the association with major or all infections 
(Table 2).
The percentage of pat ien t-quarters  with documented 
infections was significantly higher in the presence than in 
the absence of hypocomplementemia (Table 2, P < .01  for 
major, P  = .03 for all infections). The difference persisted 
a f te r  calculation of the observed-to-expected ratio for major 
and for all infections.
Three of the four patients  who died of an infection during 
the s tudy suffered from recurren t  S aureus  septicemia 
probably arising from skin ulcers. The serum samples of 
these patients  differed from the o ther  hypocomplemen- 
temic serum by the absence of CH^ activity, which dimin­
ished suddenly in the presence of high levels of lex before 
the  manifestation of the infections.
A progressive increase in the percentage of patient-quar­
te rs  with at least one documented infection became evident 
when pa t ien t-quarte rs  were grouped according to levels of 
circulating lex: under 10, 10 to 100, or over 1000 jxg Eq/mL 
(values in healthy controls, <10 jjLg Eq/mL). This increase 
was significant at the P <.01  level for major and for all infec­
tions when pat ien t-quarters  with lex under  10 jjig Eq/mL 
were compared with those with over 1000 |xg Eq/mL. The 
association between infection incidence and lex persisted 
a f te r  calculation of the observed-to-expected ratio for major 
and for all infections (Table 2).
No correlation was found between the presence of hypo­
complementemia or lex levels and the presence of skin ul­
cers, part icular  functional grades, or glucocorticosteroid
therapy. Multiple regression analysis revealed tha t  not only 
neutropenia and monocytopenia but also hypocomplemen­
temia with high lex levels, skin ulcers, and severe disability 
contributed independently to the incidence of infection in
FS.
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COMMENT
The data obtained in this study indicate that an increased 
risk of infections in FS is primarily related to peripheral 
blood PMN counts lower than 0 .1xl03/mm3 (<0.1 x 109/L). 
Other factors of importance are the presence of severe 
disability, skin ulcers, glucocorticosteroid therapy, mono­
cytopenia, hypocomplementemia, and circulating lex. In­
fections in FS are caused almost exclusively by pyogenic 
and enteric bacteria, whereas serious viral, fungal, or intra­
cellular bacterial infections, such as tuberculosis, were 
ibsent. These data are compatible with an intact immune 
system and indicate a primary defect in number or function
)f PMNs.
The role played by PMNs in host defense is important for 
jliminating facultative extracellular microorganisms, and it 
s generally accepted that neutropenia predisposes to infec- 
ion, although the level at which low PMN counts put the pa- 
ient at risk of infection differs according to the underlying 
lisease. Patients with a myelodysplastic syndrome or acute 
eukemia show an increased incidence of infections when 
>MN counts drop below 1 .5xl03/mm3 (<1.5 x 109/L), 
he effect becoming more prominent at PMN counts be- 
ween 0.1 and 0.5 x 103/mm3 (between 0.1 and 0.5 x 109/L). At 
’MN counts below 0.1xl03/mm3 (<0.1 x 109/L), there is a 
triking increase of severe infections.37'39 In idiopathic neu- 
ropenia, the correlation between an increased incidence of 
ifections accompanied by PMN counts below 0.5 x 103/mm3 
< 0 .5 x l0 9/L) has been reported to be both present and 
bsent, but the incidence and the severity of the infections 
•as considerably lower than in patients with myelodyspla- 
ia with similar neutrophil counts.4(M2 In eight series of 
atients with FS, 122 of 192 patients had a history of 
ifections.2,4,7,13,16,18'20 In two studies on the relation between 
MN counts and the occurrence of infections, PMN counts 
id not identify patients with FS at high risk of infection, 
owever, these data are difficult to interpret since no 
i etails as to the number and type of the infection were 
¿riven.2,18 The present findings in patients with FS reveal a 
gnificant correlation between the incidence of infections 
;;nd neutrophil counts below 0.1 x 103/mm3 (<0.1 x 109/L). At 
MN counts over 0.1 x 103/mm3 (>0.1 x 107L), no influence of 
MN counts on the incidence of infections was found in this 
tudy either.
In addition to neutropenia, we found other factors that 
\ ere also related to the increased risk of infections. Earlier 
i iports of infection in the rheumatoid patient stated that 
A itself predisposes to infection.5,15 Since the present 
s udy did not include control groups of patients with RA and 
i >rmal subjects, this question was not addressed directly.
he relevant question for the treatment of patients with FS 
i to identify factors that are associated with an increased 
i cidence of infection. Skin ulcers have been reported to 
occur in 19% to 50% of patients with FS2,13,18,19 and are 
t lought to be related to vasculitis, neuropathy, hypostatic 
e lema, or perforation of rheumatoid nodules.13 In the 
present study, the higher incidence of infections in the 
presence of skin ulcers was due not only to the occurrence of
infections at the site of the ulcer, but also to the presence of 
major infectious diseases such as bacteremia, osteomyeli­
tis, and septic arthritis, in which the skin ulcers functioned 
as port of entry for the microorganisms. Previous studies 
reported that bedridden patients with RA are at greater 
risk of infections of the skin, joints, and respiratory 
tract.24'27 In accordance with these findings, the severely 
debilitated patients studied herein were also found to be at 
greater risk of infection compared with those still capable of 
normal daily activities. Numerous authors have reported an 
association between glucocorticosteroid therapy and an in­
creased incidence of infections.43 In the present study, a dis­
tinct influence on the incidence of infections by glucocorti­
costeroid treatment was only seen at doses higher than 
20 mg of prednisone daily and not at lower doses. The latter 
might be explained by the very low doses with which these 
patients were generally treated. These results suggest that 
prednisone therapy in doses higher than 20 mg daily are not 
useful to treat neutropenia in patients with FS.
The present results confirm that hypocomplementemia 
and high levels of circulating lex predispose to infection, as 
described by others in selected patients with RA.21 In an 
earlier study, we found that the capacity of PMNs from 
patients with FS to ingest S aureus in the presence of serum 
containing lex as well as decreased complement activities 
to be lower than this capacity of PMNs from healthy 
controls.22 This finding suggests that the combined pres­
ence of circulating lex and hypocomplementemia leads to 
impaired host resistance to infection by hampering phago­
cytosis of bacteria by patient PMNs.
A uniformly effective treatment for neutropenia in FS 
is not available. Since the first report in 1932,44 many 
authors have recommended splenectomy for patients with 
FS with recurrent infections7,20 or for prophylactic purposes 
when PMN counts fall below 0.5 to 1.0 x 107mm3 (<0.5 to 
1.0 x 109/L).4 In 1968, Sandusky et al45 reviewed 104 cases of 
FS and found that, after splenectomy, PMN counts re­
turned to normal in 60% of the cases. In recent studies, neu­
tropenia recurred in 38 of 114 patients following splenec­
tomy,2,4,8,13,15,18'20,46 and, despite this operation, several 
patients with increased PMN counts still suffered from recur­
rent infections.2,18,20 These reports indicate that splenectomy 
is still a controversial procedure. Treatment of neutropenia 
in FS with other regimens such as glucocorticosteroids,2,18 
cytostatic drugs,47 lithium carbonate,48 d-penicillamine,49 or 
gold compounds50 have met with variable degrees of success 
and should, like splenectomy, be studied prospectively and 
on a larger scale to establish the benefits and risks of 
treatments. Treatment of neutropenia appears to be indi­
cated only in cases where the condition is severe, ie, PMN 
count under 0.1 x 103/mm3 (<0.1 x 109/L) with recurrent ma­
jor infections. Because most of the patients with FS with 
less severe neutropenia have a relatively low risk of develop­
ing major infections, we believe that these patients should 
not be routinely subjected to the potentially toxic side 
effects of any treatment if such treatment is intended solely 
to achieve an increase in the number of circulating PMNs.
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